# Starling Oncology, Inc. (STLN) > Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/starling-oncology-inc/ JSON: https://steadybase.io/company/starling-oncology-inc.json Checked Nov 10, 2026. Latest filing read: Nov 6, 2026. ## Company - Legal name: Starling Oncology, Inc. - Ticker: STLN, DFPH, STLNW (Nasdaq, OTC, Nasdaq) - SEC CIK: 0001799191 - Industry: Services-Offices & Clinics of Doctors of Medicine (SIC 8011) - Headquarters: Cerritos, CA - Fiscal year ends: December 31 - SEC filer category: Accelerated filer
Smaller reporting company - Website: theoncologyinstitute.com - LinkedIn: https://www.linkedin.com/company/oncologyinstitute - Next earnings date: Nov 12, 2026 ## Key facts - Revenue: $502.7M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/0001799191-26-000007-index.html - Operating income: -$36.1M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/0001799191-26-000007-index.html - Net income: -$60.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/0001799191-26-000007-index.html - SG&A: $105.6M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/0001799191-26-000007-index.html - Employees: 641 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm - Shares outstanding: 101,991,024 as of Nov 3, 2026 (10-Q filed Nov 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/1799191/000179919126000023/0001799191-26-000023-index.html - Auditor: Bdo Usa, P.C., Costa Mesa, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm ## Business Formed in 2007, the business of what is now The Oncology Institute, Inc. ("TOI", the "Company", "we", or "our) and its affiliated professional corporations was created initially as a collection of community oncology practices in southern California, and has evolved to be a national leader in the pursuit of reducing the ever-rising cost of oncology care, while embracing clinical best practices, state-of-the-art technology, and compassionate treatment of patients. Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm ## Annual results | Fiscal year ended | Revenue | Operating income | Net income | SG&A | |---|---|---|---|---| | Dec 31, 2025 | $502.7M | -$36.1M | -$60.6M | $105.6M | | Dec 31, 2024 | $393.4M | -$60.1M | -$64.7M | $107.8M | | Dec 31, 2023 | $324.2M | -$77.0M | -$83.1M | $113.9M | | Dec 31, 2022 | $252.5M | -$82.0M | $152,000 | $119.7M | | Dec 31, 2021 | $203.0M | -$45.9M | -$10.9M | $83.4M | Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/starling-oncology-inc.json ## Officers and directors - Daniel Virnich, Chief Executive Officer. LinkedIn: https://linkedin.com/in/danielvirnich. Source: Form 4 filed May 22, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000107997326000725/0001079973-26-000725-index.htm - Robert Ross Carter, Chief Financial Officer. LinkedIn: https://linkedin.com/in/rob-carter-09663521. Source: Form 4 filed May 22, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000107997326000723/0001079973-26-000723-index.htm - Robert Carter, Chief Financial Officer. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm - Yale Podnos, Chief Medical Officer. Source: Form 4 filed Jul 16, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000155335026000111/0001553350-26-000111-index.htm - Jeffrey Langsam, Chief Clinical Officer. Source: Form 4 filed Apr 23, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000107997326000525/0001079973-26-000525-index.htm - Kristin England, Chief Administrative Officer. Source: Form 4 filed Apr 23, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000107997326000527/0001079973-26-000527-index.htm - Anne McGeorge, Director. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm - Brad Hively, Director. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm - Karen Johnson, Director. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm - Kimberly Tzoumakas, Director. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm - Mark Pacala, Director. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm - Mark Stolper, Director. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm - Mohit Kaushal, Director. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm ## Recent 8-K events - Nov 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326001430/stln_8k.htm - Sep 2, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326001208/stln_8k.htm - Aug 21, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326001169/stln_8k.htm - Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326001006/stln_8k.htm - Aug 3, 2026: Item 5.03, Amendments to articles or bylaws; change in fiscal year; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000997/toi_8k.htm - Jul 7, 2026: Item 1.01, Entry into a material definitive agreement; Item 2.03, Creation of a direct financial obligation; Item 3.02, Unregistered sales of equity securities; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000934/toi_8k.htm - Jun 18, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1799191/000155335026000093/toi_8k.htm - May 22, 2026: Item 1.05, Material cybersecurity incident; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000721/toi_8k.htm - May 7, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000611/toi_8k.htm - Mar 13, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000304/toi_8k.htm ## Insider trades (Form 4) - Aug 21, 2026: Brad Hively (Director) sold 298,853 shares, about $1.9M. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326001175/0001079973-26-001175-index.htm - Jul 14, 2026: Yale Podnos (Chief Medical Officer) sold 23,452 shares, about $150,358. Source: https://www.sec.gov/Archives/edgar/data/1799191/000155335026000111/0001553350-26-000111-index.htm - Jun 8, 2026: Yale Podnos (Chief Medical Officer) sold 23,451 shares, about $126,166. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000801/0001079973-26-000801-index.htm - Apr 16, 2026: Mohit Kaushal (Director) sold 95,719 shares, about $335,017. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000499/0001079973-26-000499-index.htm - Jan 2, 2026: Robert Ross Carter (Chief Financial Officer) sold 247 shares, about $879. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997326000008/0001079973-26-000008-index.htm - Dec 15, 2025: Brad Hively (Director) sold 13,333 shares, about $50,265. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997325001861/0001079973-25-001861-index.htm - Nov 18, 2025: Mark L. Pacala (Director) sold 50,000 shares, about $200,000. Source: https://www.sec.gov/Archives/edgar/data/1799191/000107997325001813/0001079973-25-001813-index.htm - Sep 4, 2025: Growth I. L.P. M33 (Director) sold 6,700,000 shares, about $20.7M. Source: https://www.sec.gov/Archives/edgar/data/1799191/000121390025084700/0001213900-25-084700-index.htm - Sep 4, 2025: M. Llc Toi (Director) sold 6,700,000 shares, about $20.7M. Source: https://www.sec.gov/Archives/edgar/data/1799191/000121390025084700/0001213900-25-084700-index.htm - Sep 4, 2025: Growth I. GP LLC M33 (Director) sold 6,700,000 shares, about $20.7M. Source: https://www.sec.gov/Archives/edgar/data/1799191/000121390025084700/0001213900-25-084700-index.htm - Aug 19, 2025: Brad Hively (Director) sold 20,221 shares, about $82,097. Source: https://www.sec.gov/Archives/edgar/data/1799191/000093583625000552/0000935836-25-000552-index.htm ## Latest filings - 8-K filed Sep 2, 2026: https://www.sec.gov/Archives/edgar/data/1799191/000107997326001208/stln_8k.htm - 10-K filed Mar 12, 2026: https://www.sec.gov/Archives/edgar/data/1799191/000179919126000007/toi-20251231.htm - 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/1799191/000179919126000017/toi-20260630.htm - DEF 14A filed Apr 30, 2026: https://www.sec.gov/Archives/edgar/data/1799191/000119312526197350/d935655ddef14a.htm ## About this data SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from. Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/